新华制药子公司获非那雄胺片药品注册证书

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Group 1 - The approved Finasteride tablets are designed to treat and control BPH and to prevent urinary system events, including reducing the risk of acute urinary retention [1] - The medication can help shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]